ABC-03: A randomized phase II trial of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine (CisGem) chemotherapy for patients (pts) with advanced biliary tract cancer (ABC).
Juan W. Valle(Cancer Research UK Manchester Institute), John Bridgewater(University College London Hospitals NHS Foundation Trust), Justin S. Waters(Maidstone Hospital), Mark Jitlal(CRUK Lung Cancer Centre of Excellence), Daniel H. Palmer(University of Liverpool), Alison Backen(Cancer Research UK), Caroline Dive(University of Manchester), David Cunningham(Royal Marsden NHS Foundation Trust), Anthony Maraveyas(University of Hull), Harpreet Wasan(Hammersmith Hospital), Marian Duggan(Cancer Research UK), Paul J. Ross(King's College Hospital NHS Foundation Trust), David Alan Anthoney(St James's University Hospital), William P. Steward(University of Leicester), Sandy Beare(King's College London), Charlotte Rees(University of Southampton), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)
Cited by 5
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k